BRPI0907650A2 - Composições farmacêuticas compreendendo degradadores de produtos finais de glicosilação avançada (ages) e drogas adjuvantes como drogas anti-hipertensivas, antidiabéticas e etc - Google Patents
Composições farmacêuticas compreendendo degradadores de produtos finais de glicosilação avançada (ages) e drogas adjuvantes como drogas anti-hipertensivas, antidiabéticas e etcInfo
- Publication number
- BRPI0907650A2 BRPI0907650A2 BRPI0907650-6A BRPI0907650A BRPI0907650A2 BR PI0907650 A2 BRPI0907650 A2 BR PI0907650A2 BR PI0907650 A BRPI0907650 A BR PI0907650A BR PI0907650 A2 BRPI0907650 A2 BR PI0907650A2
- Authority
- BR
- Brazil
- Prior art keywords
- drugs
- degraders
- antihypertensive
- ages
- pharmaceutical compositions
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4422—1,4-Dihydropyridines, e.g. nifedipine, nicardipine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4436—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Diabetes (AREA)
- Cardiology (AREA)
- Hematology (AREA)
- Heart & Thoracic Surgery (AREA)
- Obesity (AREA)
- Urology & Nephrology (AREA)
- Molecular Biology (AREA)
- Vascular Medicine (AREA)
- Endocrinology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Ophthalmology & Optometry (AREA)
- Child & Adolescent Psychology (AREA)
- Emergency Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
IN152KO2008 | 2008-01-25 | ||
PCT/IN2009/000051 WO2009093264A2 (en) | 2008-01-25 | 2009-01-21 | Pharmaceutical combinations |
Publications (1)
Publication Number | Publication Date |
---|---|
BRPI0907650A2 true BRPI0907650A2 (pt) | 2015-07-21 |
Family
ID=40585608
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BRPI0907650-6A BRPI0907650A2 (pt) | 2008-01-25 | 2009-01-21 | Composições farmacêuticas compreendendo degradadores de produtos finais de glicosilação avançada (ages) e drogas adjuvantes como drogas anti-hipertensivas, antidiabéticas e etc |
Country Status (8)
Country | Link |
---|---|
US (1) | US20110034378A1 (pt) |
EP (2) | EP2659933A1 (pt) |
JP (1) | JP2011510067A (pt) |
AR (1) | AR070237A1 (pt) |
BR (1) | BRPI0907650A2 (pt) |
RU (1) | RU2010135524A (pt) |
TW (1) | TW200936134A (pt) |
WO (1) | WO2009093264A2 (pt) |
Families Citing this family (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20100072266A (ko) * | 2007-10-24 | 2010-06-30 | 머크 샤프 앤드 돔 코포레이션 | 헤테로사이클 페닐 아미드 t-형 칼슘 채널 길항제 |
ES2448398T3 (es) * | 2011-06-03 | 2014-03-13 | Ratiopharm Gmbh | Composición farmacéutica que comprende dapagliflozina y ciclodextrina |
US9480755B2 (en) * | 2011-06-03 | 2016-11-01 | Ratiopharm Gmbh | Pharmaceutical composition comprising dapagliflozin and cyclodextrin |
WO2013030725A1 (en) * | 2011-08-26 | 2013-03-07 | Wockhardt Limited | Methods for treating cardiovascular disorders |
PL3280447T3 (pl) * | 2015-04-08 | 2019-07-31 | Torrent Pharmaceuticals Limited | Preparaty farmaceutyczne |
WO2016191294A1 (en) * | 2015-05-22 | 2016-12-01 | The Trustees Of Columbia University In The City Of New York | Sk and ik channel agonists for treatment of heart failure |
TWI672299B (zh) | 2015-06-03 | 2019-09-21 | 美商必治妥美雅史谷比公司 | 4-羥基-3-(雜芳基)吡啶-2-酮apj促效劑 |
FR3040303B1 (fr) * | 2015-08-27 | 2019-04-05 | Les Laboratoires Servier Suivi Par Sabine Goudeau-Wenger | Composition pharmaceutique comprenant un inhibiteur de la hmg-coa reductase et un inhibiteur eca |
CA3059210C (en) | 2016-05-19 | 2022-07-19 | The Regents Of The University Of California | Triple drug combination (metformin, simvastatin, digoxin) for targeted treatment of pancreatic cancer |
TW202404581A (zh) | 2022-05-25 | 2024-02-01 | 美商醫肯納腫瘤學公司 | Mek抑制劑及其用途 |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5614492A (en) | 1986-05-05 | 1997-03-25 | The General Hospital Corporation | Insulinotropic hormone GLP-1 (7-36) and uses thereof |
US20010018524A1 (en) * | 1999-10-06 | 2001-08-30 | Alangudi Sankaranarayanan | Novel compounds for the management of aging-related and diabetic vascular complications, process for their preparation and therapeutic uses thereof |
ATE260256T1 (de) * | 1999-10-06 | 2004-03-15 | Torrent Pharmaceuticals Ltd | Pyridinium-derivate zur behandlung von altersbedingten und diabetischen vaskulären komplikationen, verfahren zu ihrer herstellung und ihre pharmazeutischen anwendungen |
DE60111919T2 (de) * | 2001-03-21 | 2006-04-20 | Torrent Pharmaceuticals Ltd., Ahmedabad | Pyridiniumverbindungen zur Behandlung von AGE-relatierten Krankheiten |
KR100785109B1 (ko) * | 2001-04-05 | 2007-12-12 | 토렌트 파마슈티칼스 리미티드 | 노화 관련 및 당뇨병 혈관성 합병증에 사용되는 헤테로사이클릭 화합물 |
WO2006002983A1 (en) * | 2004-07-06 | 2006-01-12 | Novartis Ag | Combination of organic compounds |
TW200745066A (en) | 2005-09-16 | 2007-12-16 | Torrent Pharmaceuticals Ltd | Novel PTP1B inhibitors |
MX2008011227A (es) | 2006-03-03 | 2009-02-10 | Torrent Pharmaceuticals Ltd | Receptores antagonistas de accion nueva y doble en los receptores at1 y eta. |
-
2009
- 2009-01-21 US US12/735,472 patent/US20110034378A1/en not_active Abandoned
- 2009-01-21 EP EP13158596.0A patent/EP2659933A1/en not_active Withdrawn
- 2009-01-21 WO PCT/IN2009/000051 patent/WO2009093264A2/en active Application Filing
- 2009-01-21 JP JP2010543629A patent/JP2011510067A/ja active Pending
- 2009-01-21 BR BRPI0907650-6A patent/BRPI0907650A2/pt not_active IP Right Cessation
- 2009-01-21 RU RU2010135524/15A patent/RU2010135524A/ru not_active Application Discontinuation
- 2009-01-21 EP EP09704262A patent/EP2254563A2/en not_active Withdrawn
- 2009-01-23 AR ARP090100206A patent/AR070237A1/es unknown
- 2009-01-23 TW TW098102750A patent/TW200936134A/zh unknown
Also Published As
Publication number | Publication date |
---|---|
RU2010135524A (ru) | 2012-02-27 |
US20110034378A1 (en) | 2011-02-10 |
JP2011510067A (ja) | 2011-03-31 |
EP2659933A1 (en) | 2013-11-06 |
EP2254563A2 (en) | 2010-12-01 |
WO2009093264A3 (en) | 2009-10-22 |
AR070237A1 (es) | 2010-03-25 |
WO2009093264A2 (en) | 2009-07-30 |
TW200936134A (en) | 2009-09-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BRPI0907650A2 (pt) | Composições farmacêuticas compreendendo degradadores de produtos finais de glicosilação avançada (ages) e drogas adjuvantes como drogas anti-hipertensivas, antidiabéticas e etc | |
BRPI0910503A2 (pt) | compostos, composições farmacêuticas e respectivos usos. | |
IL228402A0 (en) | Nitro-cyclic compounds, their pharmaceutical preparations and their uses | |
IL204844A (en) | Coinolone analogues, pharmaceuticals containing them and their uses | |
IL195488A (en) | Compounds, pharmaceuticals containing them and their uses | |
IL216254A (en) | Compounds, pharmaceutical compositions and their uses | |
IL203915A (en) | Annotations of 2-Benzylphenyl-6-Hydroxymethyl-Tetrahydro-2 H-Pyrene-3,4,5-Triol | |
BRPI0718688A2 (pt) | Composições de baixa irritação e métodos para preparar as mesmas. | |
IL206808A (en) | Indolyl-pyridone history, their pharmaceutical preparations and their uses | |
IL211400A0 (en) | Substituted aminoindanes and analogs thereof, and the pharmaceutical use thereof | |
BRPI1012892A2 (pt) | composto, e, composição farmacêutica. | |
IL198289A (en) | Processed dihydropyrazolones, processes for their preparation, medicinal preparations containing them and their use in the preparation of medicinal preparations | |
IL205880A0 (en) | Aminoglycoside analogs, compositions comprising the same and uses thereof | |
IL206395A (en) | N- Heterocyclic-7-Oxo-6-Sulphoxy-6,1-Diazabicyclo [1.2.3] Octane-2-Carboxamides and Pharmaceuticals Containing Them | |
BRPI0909030A2 (pt) | composições farmacêuticas de liberação modificada compreendendo micofenolato e processos para as mesmas. | |
NL2000690A1 (nl) | Gestabiliseerde farmaceutische samenstellingen omvattende fesoterodine. | |
DK2139494T3 (da) | Farmaceutiske formuleringer, der indeholder dapagliflozin-propylenglycolhydrat | |
DK3984528T3 (da) | Farmaceutiske sammensætninger, som omfatter nilotinib | |
BRPI0815773A2 (pt) | composto, e, medicamento. | |
BRPI0813455A2 (pt) | Derivado de 17beta-ciano-18a-homo-19-nor-androst-4-eno, seu uso e medicamentos contendo este derivado. | |
BRPI0820997A2 (pt) | Comprimidos de desintegração oral compreendendo difenidramina. | |
BRPI0807078A2 (pt) | Composto, e, formulação farmacêutica | |
BR112012003800A2 (pt) | composição, peptídeo, e formulação farmacêutica. | |
IL195813A0 (en) | Substituted aminopyrazolopyridines and salts thereof, their preparations and pharmaceutical compositions comprising them | |
BRPI0820673A2 (pt) | Formulações e composições farmacêuticas de fenilefrina para absorção transmucosal |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE AS 6A E 7A ANUIDADES. |
|
B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2344 DE 08-12-2015 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013. |